BRH Medical创新伤口愈合疗法在美国和中国获得专利

2016-11-09 佚名 BRH Medical

经临床证实,该系统能够减少伤口疼痛并加快伤口愈合。

BRH Medical今天宣布,该公司用于治疗糖尿病腿部创伤、静脉腿部溃疡和压力性溃疡的创新伤口愈合系统已经在美国和中国获得专利。中国专利涉及皮肤溃疡的治疗,而美国专利与商标局颁发的专利涉及治疗皮肤溃疡的技术以及系统内先进的文档技术。

BRH Medical首席执行官Motti Oderberg表示:“中美市场的专利凸显了我们伤口愈合产品的独特性。两个市场都有巨大的市场潜力,在这些国家获得专利意味着渗透进这些市场过程中的一大进步。”

BRH伤口治疗解决方案集成了超声与电子功能。每个系统配备内置数字图片测量集成以及用于追踪伤口愈合进展的文档软件。

BRH Medical首席技术官兼专利技术发明人Ilan Feferberg表示:“我一直渴望开发一款能够真正帮助人们治愈伤口的产品。我们的患者十分感谢这款产品,他们就是技术有效的最好证明。”

经临床证实,该系统能够减少伤口疼痛并加快伤口愈合。一份已出版研究相关的报告表明,经过一个月的治疗,超过50%的糖尿病足溃疡患者表现出良好疗效,并且伤口实现愈合。

Oderberg先生表示:“伤口愈合产品市场十分庞大,并且不断增长,我们希望成为治疗各种长期伤口(包括压力性伤口、糖尿病腿部创伤和局部缺血造成的伤口)的黄金级标准。”

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1858697, encodeId=4230185869ecd, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Wed Oct 25 06:28:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285293, encodeId=bc71128529331, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Fri Nov 11 05:28:00 CST 2016, time=2016-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309850, encodeId=89aa13098506e, content=<a href='/topic/show?id=5e6926003ae' target=_blank style='color:#2F92EE;'>#伤口愈合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26003, encryptionId=5e6926003ae, topicName=伤口愈合)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Fri Nov 11 05:28:00 CST 2016, time=2016-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533550, encodeId=2e9015335503b, content=<a href='/topic/show?id=7583114e529' target=_blank style='color:#2F92EE;'>#Medical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11475, encryptionId=7583114e529, topicName=Medical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbe912466517, createdName=海豹, createdTime=Fri Nov 11 05:28:00 CST 2016, time=2016-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607183, encodeId=03a1160e18393, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Nov 11 05:28:00 CST 2016, time=2016-11-11, status=1, ipAttribution=)]
    2017-10-25 jeanqiuqiu
  2. [GetPortalCommentsPageByObjectIdResponse(id=1858697, encodeId=4230185869ecd, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Wed Oct 25 06:28:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285293, encodeId=bc71128529331, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Fri Nov 11 05:28:00 CST 2016, time=2016-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309850, encodeId=89aa13098506e, content=<a href='/topic/show?id=5e6926003ae' target=_blank style='color:#2F92EE;'>#伤口愈合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26003, encryptionId=5e6926003ae, topicName=伤口愈合)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Fri Nov 11 05:28:00 CST 2016, time=2016-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533550, encodeId=2e9015335503b, content=<a href='/topic/show?id=7583114e529' target=_blank style='color:#2F92EE;'>#Medical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11475, encryptionId=7583114e529, topicName=Medical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbe912466517, createdName=海豹, createdTime=Fri Nov 11 05:28:00 CST 2016, time=2016-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607183, encodeId=03a1160e18393, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Nov 11 05:28:00 CST 2016, time=2016-11-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1858697, encodeId=4230185869ecd, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Wed Oct 25 06:28:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285293, encodeId=bc71128529331, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Fri Nov 11 05:28:00 CST 2016, time=2016-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309850, encodeId=89aa13098506e, content=<a href='/topic/show?id=5e6926003ae' target=_blank style='color:#2F92EE;'>#伤口愈合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26003, encryptionId=5e6926003ae, topicName=伤口愈合)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Fri Nov 11 05:28:00 CST 2016, time=2016-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533550, encodeId=2e9015335503b, content=<a href='/topic/show?id=7583114e529' target=_blank style='color:#2F92EE;'>#Medical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11475, encryptionId=7583114e529, topicName=Medical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbe912466517, createdName=海豹, createdTime=Fri Nov 11 05:28:00 CST 2016, time=2016-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607183, encodeId=03a1160e18393, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Nov 11 05:28:00 CST 2016, time=2016-11-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1858697, encodeId=4230185869ecd, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Wed Oct 25 06:28:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285293, encodeId=bc71128529331, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Fri Nov 11 05:28:00 CST 2016, time=2016-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309850, encodeId=89aa13098506e, content=<a href='/topic/show?id=5e6926003ae' target=_blank style='color:#2F92EE;'>#伤口愈合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26003, encryptionId=5e6926003ae, topicName=伤口愈合)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Fri Nov 11 05:28:00 CST 2016, time=2016-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533550, encodeId=2e9015335503b, content=<a href='/topic/show?id=7583114e529' target=_blank style='color:#2F92EE;'>#Medical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11475, encryptionId=7583114e529, topicName=Medical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbe912466517, createdName=海豹, createdTime=Fri Nov 11 05:28:00 CST 2016, time=2016-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607183, encodeId=03a1160e18393, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Nov 11 05:28:00 CST 2016, time=2016-11-11, status=1, ipAttribution=)]
    2016-11-11 海豹
  5. [GetPortalCommentsPageByObjectIdResponse(id=1858697, encodeId=4230185869ecd, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Wed Oct 25 06:28:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285293, encodeId=bc71128529331, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Fri Nov 11 05:28:00 CST 2016, time=2016-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309850, encodeId=89aa13098506e, content=<a href='/topic/show?id=5e6926003ae' target=_blank style='color:#2F92EE;'>#伤口愈合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26003, encryptionId=5e6926003ae, topicName=伤口愈合)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Fri Nov 11 05:28:00 CST 2016, time=2016-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533550, encodeId=2e9015335503b, content=<a href='/topic/show?id=7583114e529' target=_blank style='color:#2F92EE;'>#Medical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11475, encryptionId=7583114e529, topicName=Medical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbe912466517, createdName=海豹, createdTime=Fri Nov 11 05:28:00 CST 2016, time=2016-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607183, encodeId=03a1160e18393, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Nov 11 05:28:00 CST 2016, time=2016-11-11, status=1, ipAttribution=)]

相关资讯

Nature:糖尿病为何“那么坏”,是“免疫细胞”在作祟!

炎症是糖尿病患者会产生心脏病、中风、肾病和其它相关并发症的主要原因之一。11月2日,在线发表于Nature杂志上的一项研究中,华盛顿大学的科学家们鉴定出了慢性炎症一种可能的触发机制。原来,又是一种免疫细胞在作怪。炎症是糖尿病患者会产生心脏病、中风、肾病和其它相关并发症的主要原因之一。11月2日,在线发表于Nature杂志上的一项研究中(论文题目:Fatty acid synthesis confi

Cell:协和医学院李平平教授等揭示二型糖尿病逆转新希望

最近,中国医学研究院北京协和医学院的李平平教授和美国加州大学圣地亚哥分校Jerrold M. Olefsky教授的联合团队在糖尿病及肥胖症研究领域取得重要发现,揭示了通过阻断galectin-3 (Gal3)这一蛋白,可以有效逆转糖尿病或肥胖症模型小鼠的胰岛素抵抗和葡萄糖不耐受等症状。这一成果发表于近期的《Cell》期刊上。▲李平平教授(左)和Jerrold M. Olefsky教授(右)(图片来

CELL MET:同样是胖子为何有人不得糖尿病?Cell子刊给出新答案

几年以前,科学家们就已经发现有些瘦人最终也会得糖尿病,而一些比较胖的人反而能一直保持健康。现在来自犹他大学健康学院的科学家们发现了这一谜题的一个可能答案:一类具有毒性的脂肪代谢产物——神经酰胺——可能会让人易患2型糖尿病。相关研究结果发表在国际学术期刊Cell Metabolism上,该研究发现神经酰胺的积累会影响脂肪组织的正常功能。当人们吃的过多,体内就会产生过量的脂肪酸,有些脂肪酸能够储存为甘

Cell子刊:同样是胖子为何有人不得糖尿病?

几年以前,科学家们就已经发现有些瘦人最终也会得糖尿病,而一些比较胖的人反而能一直保持健康。现在来自犹他大学健康学院的科学家们发现了这一谜题的一个可能答案:一类具有毒性的脂肪代谢产物——神经酰胺——可能会让人易患2型糖尿病。相关研究结果发表在国际学术期刊Cell Metabolism上,该研究发现神经酰胺的积累会影响脂肪组织的正常功能。当人们吃的过多,体内就会产生过量的脂肪酸,有些脂肪酸能够储存为甘

新血脂指南:走中国路 穿中国鞋(2016年修订版)

10月24日,《中国成人血脂异常防治指南(2016年修订版)》重磅发布,新指南距2007年发布的上一版指南已接近十年。新指南有哪些更新变化?哪些关键要点值得关注?本期,特为读者奉上指南撰写专家和心血管领域专家的权威解读。 集本土化、权威性、公益性、科学性于一身▲北京大学人民医院心脏中心  胡大一近十年来,血脂领域国际国内的研究和观点发生了巨大变化,血脂指南的更新势在必行。从